Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Morphine
Drug ID BADD_D01498
Description Morphine, the main alkaloid of opium, was first obtained from poppy seeds in 1805.[A176035] It is a potent analgesic, though its use is limited due to tolerance, withdrawal, and the risk of abuse.[A176050] Morphine is still routinely used today, though there are a number of semi-synthetic opioids of varying strength such as [codeine], [fentanyl], [methadone], [hydrocodone], [hydromorphone], [meperidine], and [oxycodone]. Morphine was granted FDA approval in 1941.[L12114]
Indications and Usage Morphine is used for the management of chronic, moderate to severe pain.[A176050] Opiods, including morphine, are effective for the short term management of pain. Patients taking opioids long term may need to be monitored for the development of physical dependence, addiction disorder, and drug abuse.[L5728]
Marketing Status approved; investigational
ATC Code N02AA01
DrugBank ID DB00295
KEGG ID D08233
MeSH ID D009020
PubChem ID 5288826
TTD Drug ID D0WE3O
NDC Product Code 42799-217
UNII 76I7G6D29C
Synonyms Morphine | Morphia | Morphine Chloride | Chloride, Morphine | Morphine Sulfate | Sulfate, Morphine | SDZ 202-250 | SDZ 202 250 | SDZ 202250 | SDZ202-250 | SDZ202 250 | SDZ202250 | Morphine Sulfate (2:1), Pentahydrate | MS Contin | Contin, MS | Oramorph SR | Duramorph | Morphine Sulfate (2:1), Anhydrous
Chemical Information
Molecular Formula C17H19NO3
CAS Registry Number 57-27-2
SMILES CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Deafness bilateral04.02.01.0070.000111%Not Available
Drug tolerance08.06.01.0030.001236%Not Available
Drug tolerance decreased08.06.01.0240.000111%Not Available
Cardiac flutter02.03.02.0120.000111%Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Organ failure08.01.03.0410.000167%Not Available
Inappropriate antidiuretic hormone secretion14.05.07.001; 05.03.03.001--Not Available
Skin swelling23.03.03.0390.000167%Not Available
Infusion site pain12.07.05.002; 08.02.05.0140.000813%Not Available
Infusion site swelling12.07.05.003; 08.02.05.002--Not Available
Infusion site pruritus23.03.12.006; 12.07.05.005; 08.02.05.0040.000356%Not Available
Affect lability19.04.01.001--Not Available
Skin burning sensation23.03.03.021; 17.02.06.009--Not Available
Cerebral disorder17.02.10.0170.000223%Not Available
Faecaloma07.01.03.0040.000780%Not Available
Gaze palsy17.02.05.044; 06.05.02.0140.000111%Not Available
Faecalith07.01.03.007--Not Available
Major depression19.15.01.0030.000167%Not Available
Metabolic disorder14.11.01.0010.000301%Not Available
Pulseless electrical activity02.03.04.0200.000356%Not Available
Reperfusion arrhythmia02.03.02.0100.000111%Not Available
Hypogonadism21.03.02.010; 05.05.04.002--Not Available
Vasodilation procedure25.03.01.001--Not Available
Disturbance in sexual arousal19.08.04.003--Not Available
Venous occlusion24.04.02.0090.000111%Not Available
Angiopathy24.03.02.007--Not Available
Haemorrhagic urticaria23.04.02.005; 10.01.06.005--Not Available
Induration08.01.03.020--Not Available
Adverse event08.06.01.010--Not Available
Brain neoplasm17.20.01.003; 16.30.01.003--Not Available
The 15th Page    First    Pre   15 16 17 18 19    Next   Last    Total 20 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene